CN101757629A - Medicine composition for treating acute and chronic aryngitis and preparation method thereof - Google Patents
Medicine composition for treating acute and chronic aryngitis and preparation method thereof Download PDFInfo
- Publication number
- CN101757629A CN101757629A CN201010108427A CN201010108427A CN101757629A CN 101757629 A CN101757629 A CN 101757629A CN 201010108427 A CN201010108427 A CN 201010108427A CN 201010108427 A CN201010108427 A CN 201010108427A CN 101757629 A CN101757629 A CN 101757629A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- medicine
- spray
- preparation
- dissolving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000001154 acute effect Effects 0.000 title claims abstract description 13
- 230000001684 chronic effect Effects 0.000 title abstract description 7
- 229940079593 drug Drugs 0.000 title description 2
- 239000007921 spray Substances 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000012153 distilled water Substances 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims abstract description 9
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 8
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 8
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 201000007100 Pharyngitis Diseases 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 claims description 17
- 229940046011 buccal tablet Drugs 0.000 claims description 13
- 239000006189 buccal tablet Substances 0.000 claims description 13
- 239000003862 glucocorticoid Substances 0.000 claims description 12
- 208000016150 acute pharyngitis Diseases 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 229960002152 chlorhexidine acetate Drugs 0.000 claims description 9
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims description 9
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 8
- 229960003260 chlorhexidine Drugs 0.000 claims description 8
- 239000011812 mixed powder Substances 0.000 claims description 8
- 230000002421 anti-septic effect Effects 0.000 claims description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 6
- 239000007923 nasal drop Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000007779 soft material Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 abstract description 15
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 230000001954 sterilising effect Effects 0.000 abstract description 2
- 239000003246 corticosteroid Substances 0.000 abstract 3
- 229960001334 corticosteroids Drugs 0.000 abstract 3
- 229940100662 nasal drops Drugs 0.000 abstract 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 2
- 239000013078 crystal Substances 0.000 abstract 2
- 229940041616 menthol Drugs 0.000 abstract 2
- 239000007935 oral tablet Substances 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- 230000002335 preservative effect Effects 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- 235000009161 Espostoa lanata Nutrition 0.000 description 10
- 240000001624 Espostoa lanata Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 210000003800 pharynx Anatomy 0.000 description 9
- 230000000954 anitussive effect Effects 0.000 description 8
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000003032 molecular docking Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010018691 Granuloma Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VOBDXTSTTMAKHK-VHDCPBDGSA-N 3870-07-3 Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O VOBDXTSTTMAKHK-VHDCPBDGSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000008508 epithelial proliferation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010070245 Foreign body Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- -1 diammonium glycyrrhizinate compound Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a medicine composition for treating acute and chronic aryngitis and a preparation method thereof. The medicine composition comprises corticosteroids, inflammation-diminishing preservative with inflammation-diminishing sterilizing function, glycyrrhizic acid traditional Chinese medicines with anti-inflammatory and antianaphylaxis and cough-relieving function, menthol crystal and the like. The medicine composition is characterized by comprising 0.05-0.5 percent of corticosteroids, 0.015-0.15 percent of inflammation-diminishing preservative and 0.05-0.5 percent of glycyrrhizic acid traditional Chinese medicines. Preparations of the medicine composition comprise spray, nose drops, oral solutions, oral tablets, granules and the like, preferably, the spray or nose drops or oral tablets. The preparation method of the spray comprises the following steps of: dissolving surfactant by using distilled water, dropping a proper amount of Tween 80; stirring for dissolving, respectively adding a corticosteroids water solution, a glycyrrhizic acid traditional Chinese medicines water solution and a proper amount of menthol crystal water solution, and ultrasonically mixing uniformly. The traditional Chinese medicine and western medicine compound spray or nose drops for treating the acute and chronic aryngitis have scientific formula, convenient use, high local medicine concentration and accurate clinical treatment effect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of acute/chronic pharyngitis and preparation method thereof.
Background technology
Pharyngolaryngitis is a pharyngeal mucosa, the inflammation of submucous tissue, and as clinical frequently-occurring disease, serious threat and have influence on the healthy of people.The acute pharyngitis symptom feature is a red swelling of the pharynx, and scorching hot pain has the sense of stopping up in the larynx, and it is unfavorable to swallow pain, and hoarseness often has heating, aversion to cold, and red tongue, arteries and veins be how floating number, and these mostly are hot and suffocating owing to having in the patient, feel exopathogen again, attack within and outside to cause in throat.Weight person also General Symptoms may occur, such as fear of cold, hyperpyrexia, headache, inappetence, xerostomia etc.Mostly chronic pharyngitis is thoroughly not to be transformed by the acute pharyngitis treatment, also have because of repeated cold, and hyperactivity of deficient fire, the lung yin of burning, the fumigation throat is caused.Chronic pharyngitis is mainly divided following a few class: one is chronic simple pharyngitis and chronic hypertrophic pharyngitis, also has atrophic or pharyngitis sicca.Symptom comprises the pharyngeal various senses of discomfort that are painted with, itch, burning sensation, hypodynias etc. because secretions stimulates the releasing stimulus cough, but also can cause otitis media, sinusitis, laryngitis, tracheobronchitis and pneumonia, the acute festering type pharyngitis, when serious even can concurrent acute nephritis, rheumatic fever and septicemia etc.The cardinal symptom characteristics are foreign body in pharynx senses, itch and cough, no expectorant, sound or hoarse or modify tone.Cause the factor of pharyngolaryngitis to have multiple, pathogenic microorganism is the main paathogenic factor of acute pharyngitis, physics or chemical irritation, as talk too much, pungent, the boiling hot hot drink food of happiness food, tobacco and wine are excessive, air pollutions such as chemical gas, dust, all can damage pharyngeal mucosa epithelium and body of gland, destroy the local defense system.Weather, pharynx in season element can cause the pharyngeal mucosa vasoconstriction as cold, the phagocyte decreased number, and local resistance descends; Drying can influence pharyngeal mucous secretion and cilium wriggling, reduces cleaning, humidification to air, and directly pharyngeal mucosa being caused stimulates and infringement; The winter-spring season climate change is big, and the room air circulation is poor, causes easily that also resistance descends and the pathogenic microorganism invasion.The acute and chronic inflammation of adjacent organs also can be invaded pharyngeally along mucosa, submucous tissue, regional nodes and blood circulation, or the repetitious stimulation of rheuminess thing is pharyngeal, or cacorhinia breathes and be obstructed and be forced to mouth breathing etc., all can cause pharyngitis.
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical composition for the treatment of acute/chronic pharyngitis, described pharmaceutical composition comprises the effective ingredient of following components by weight percent: glucocorticoid medicine 0.01-1.00%, antiinflammatory antiseptic 0.01-0.50%, Radix Glycyrrhizae acids medicine 0.02-1.00%.
Glucocorticoid medicine is dexamethasone and derivant, triamcinolone acetonide and derivant thereof, budesonide and derivant thereof, hydrocortisone and salt thereof in the described pharmaceutical composition; The antiinflammatory antiseptic is the chlorhexidine or derivatives thereof; The scorching medicine of glycyrrhizic acid is glycyrrhizic acid, ammonium glycyrrhizinate, diammonium glycyrrhizinate.
Preferably, described pharmaceutical composition comprises the effective ingredient of following components by weight percent: glucocorticoid medicine 0.05-0.15%, antiinflammatory antiseptic 0.05-0.10%, Radix Glycyrrhizae acids medicine 0.1-0.3%.
Described pharmaceutical composition is tablet, granule, oral administration solution, spray, nasal drop.
Preferably, described pharmaceutical composition is spray, buccal tablet and nasal drop.
The preparation method of described spray or nasal drop is as follows: with chlorhexidine acetate 0.5～1g 300ml dissolved in distilled water, add the Tween 80 of 5～50g with the 300ml dissolved in distilled water, behind the stirring and dissolving mixing, add respectively again dissolving 0.5～1.5g glucocorticoid medicine aqueous solution 100ml, dissolving 1～3g diammonium glycyrrhizinate aqueous solution 100ml and be dissolved in the 5g Mentholum of 200ml hot water, ultrasonic mix homogeneously gets final product.
The preparation method of described buccal tablet is as follows: glucocorticoid medicine 0.4-1.5g, and chlorhexidine acetate 0.4-1.5g, diammonium glycyrrhizinate 0.8-2.5g with 100g Fructus Hordei Germinatus glucide mixing, sieves respectively, adds the 450g Icing Sugar again, sieves, and obtains mixed-powder; Will be an amount of (buccal tablet weight 0.5%) Mentholum be dissolved in the 150ml dehydrated alcohol, add mix homogeneously in the mixed powder, oven dry, with 100ml 60% syrup or 1%HPMC solution 120ml is binding agent, system soft material and granulations of sieving, granulate tabletting, compound recipe buccal tablet that must the heavily about 0.4-1.5g/ sheet of sheet.
Dexamethasone sodium phosphate (triamcinolone acetonide, cortisone) is a kind of glucocorticoid medicine, and its mechanism of action is: (1) antiinflammatory action: glucocorticoid alleviates and prevents to organize reaction to inflammation, thus the performance that reduces inflammation.(2) antiallergic, immunosuppressive action: prevent or suppress the mesomeric immunoreation of cell, the anaphylaxis of retardance, and alleviate former immunoreation ground expansion.Chlorhexidine is a Cidex-7, has great broad-spectrum antibacterial, bactericidal action, and is all effective to gram positive bacteria and gram negative bacteria.Some staphylococcus, Streptococcus mutans, streptococcus salivarius, Candida albicans, escherichia coli, anaerobism bacterium acidi propionici are extremely sensitive; To the medium degree sensitivity of bloodthirsty streptococcus, low responsive to Proteus, Rhodopseudomonas, Kleb and Grain-negative coccus (as Veillonella).This product is adsorbed on the permeability barrier of antibacterial endochylema film, and cellular content is spilt, and low concentration suppresses antibacterial, high concentration kill bacteria.Dexamethasone sodium phosphate and chlorhexidine acetate share and can strengthen the antiinflammatory bactericidal action, alleviate the symptom of acute/chronic pharyngitis faster.Diammonium glycyrrhizinate has stronger antiinflammatory and antitussive effect, can protect pharyngeal and bronchial mucosa is avoided stimulating, and acts on throat's peripheral nerve weakening cough, thereby reaches cough suppressing effect.And wherein contain the purpose that glycyrrhizin can reach flavoring.
The local excitation test of treatment acute/chronic pharyngitis spray of the present invention: select 6 of 2.5kg healthy rabbits, this three kinds of sprays are used in the throat.Respectively choose 3 disposable heavy doses and be sprayed on oral cavity and bottleneck throat, observe and record 24h partial reacting phenomenon behind the 72h.The result shows: medication 24h, there is no local excitation phenomenons such as rubescent, dermexanthesis, vesicle behind the 72h, and illustrate that this preparation does not have acute irritation; Respectively get 3 rabbit oral cavities every day and throat spray 3 times in addition, observe after spraying 14d continuously, still all do not send out local excitation phenomenons such as seeing rubescent, dermexanthesis, vesicle.Illustrate that said preparation does not have chronic cumulative bad irritant reaction.
The specific embodiment
Following examples are used to further specify the present invention, but do not limit the scope of the invention.
Experimental example 1: preparation spray
With chlorhexidine acetate 0.5-1g 300ml dissolved in distilled water, add the 5-50g dissolved Tween 80 of 300ml, behind the stirring and dissolving mixing, add aqueous solution 100ml that dissolves 0.5-1.5g dexamethasone sodium phosphate aqueous solution 100ml, dissolving 1-3g diammonium glycyrrhizinate and the 5g Mentholum that is dissolved in 200ml hot water more respectively, ultrasonic mix homogeneously gets final product colourless transparent solution.
Experimental example 2: preparation spray
With chlorhexidine acetate 0.5-1g 300ml dissolved in distilled water, add the Tween 80 of 5-50g with the 300ml dissolved in distilled water, behind the stirring and dissolving mixing, add aqueous solution 100ml, the dissolving 1-3g diammonium glycyrrhizinate aqueous solution 100ml of dissolving 0.5-1.5g triamcinolone acetonide acetate more respectively and be dissolved in the 5g Mentholum of 200ml hot water, ultrasonic mix homogeneously get final product the milky suspension.
Experimental example 3: preparation spray
With chlorhexidine gluconate 0.5-1g 300ml dissolved in distilled water, add the 5-50g dissolved Tween 80 of 300ml, behind the stirring and dissolving mixing, add aqueous solution 100ml, the dissolving 1-3g glycyrrhizic acid aqueous solution 100ml of dissolving 0.5-1.5g hydrocortisone more respectively and be dissolved in the 5g Mentholum of 200ml hot water, ultrasonic mix homogeneously get final product the milky suspension.
Experimental example 4: preparation buccal tablet
With dexamethasone sodium phosphate 4-12g, add 100g Fructus Hordei Germinatus glucide mixing, sieve (1); Chlorhexidine acetate 4-12g adds mannitol 100g mixing, sieve (2); Diammonium glycyrrhizinate 8-24g adds 100g Fructus Hordei Germinatus glucide mixing, sieve (3); With (1) (2) (3) mix homogeneously, add the 450g Icing Sugar, sieve, obtain mixed-powder; Will be an amount of (buccal tablet weight 0.5%) Mentholum be dissolved in the 150ml dehydrated alcohol, add mix homogeneously in the mixed powder, 60 ℃ of oven drying 1h, with 100ml60% syrup or 1%HPMC solution 120ml is binding agent, the suitable soft material of system, 18 mesh sieves are granulated, 60 ℃ of dry 2h, 16 order nylon mesh granulate, the magnesium stearate that adds buccal tablet weight 0.5%, mixing, oval special-shaped stamping, get 1000, the heavily about 0.8g/ sheet of sheet.
Experimental example 5: preparation buccal tablet
With triamcinolone acetonide acetate 4-12g, add 150g Fructus Hordei Germinatus glucide mixing, sieve (1); Chlorhexidine acetate 4-12g adds mannitol 150g mixing, sieve (2); Diammonium glycyrrhizinate 8-24g adds 150g Fructus Hordei Germinatus glucide mixing, sieve (3); With (1) (2) (3) mix homogeneously, add the 350g Icing Sugar, sieve, obtain mixed-powder.Sheet weighs 0.5% Mentholum and is dissolved in the 150ml dehydrated alcohol, adds in the mixed-powder mix homogeneously, 60 ℃ of oven drying 1h are binding agent with 100ml60% syrup or 5%HPMC solution 120ml, the suitable soft material of system, 18 mesh sieves are granulated, 60 ℃ of dry 2h, 16 order nylon mesh granulate, the magnesium stearate of adding buccal tablet weight 0.5%, mixing, oval special-shaped stamping gets 1000, the heavily about 0.8g/ sheet of sheet.
The animal pharmacodynamic study
Experiment one: the antiinflammatory of spray of the present invention and immunoregulation effect
Three kinds of sprays of the present invention are mainly used in the various acute/chronic pharyngitis of treatment.Pharmacological research shows that three kinds of sprays of the present invention have extraordinary antiinflammatory action, antitussive effect and antibacterial action.
1 material
Kunming mouse, body weight 20-24g; SD rat and Wistar rat, body weight (200 ± 20) g, the male and female dual-purpose provides by Military Medical Science Institute's Experimental Animal Center.
2 methods and result
2.1 the antiinflammatory action of three kinds of sprays of the present invention
2.1.1 the foundation of rat acute inflammatory model and the detection of index
40 Wistar rats are divided into 4 groups of modeling groups, natural recovering group, counterevidence group, blank group, 10 every group at random.The modeling group: the upper and lower noon of 1-3d respectively sprays its pharyngeal 1 time with 15% ammonia, presses with aerosol apparatus spray 3 at every turn.Blood smear is got in the 4d docking.Compound spray treatment group: pharyngeal spray ammonia is with the modeling group.To rat spray self-control Chinese medicine and western medicine compound spray (according to big and rat body surface coefficient conversion), every day 2 times, each 2 press 4-7d with laryngeal spray.Blood smear is got in the 8d docking.Blank group: spray equivalent distilled water.Positive controls: spray waits the dexamethasone sodium phosphate of dosage folk prescription.Blood smear is got in 4d docking, after each treated animal is got blood smear, takes off pharyngeal mucosa immediately behind the femoral artery sacrificed by exsanguination animal and undertissue makes sections observation.Docking was got blood smear and is measured routine blood test before each treated animal was put to death.
Experimental result shows: by the pharyngeal pathological examination, the outer keratinization of mucous epithelium of model group and blank group rat pharynx tissue, part comes off, the obvious hypertrophy of mucous epithelium layer, tela submucosa is thin, and the obvious hypertrophy of part mucous gland epithelial layer does not have obvious demarcation line with lamina propria, little vasodilation, hyperemia, edema in the lamina propria have a large amount of inflammatory cell infiltrations between lamina propria zone and mucous gland.With the pathological manifestations basically identical of clinical acute pharyngitis, model is more successful.
Compound spray treatment treated animal pharyngeal is basic, and the pharyngeal epithelial proliferation is not obvious, does not see congested phenomenon substantially near normal, and blood vessel negligible amounts cell infiltration is based on slightly; Positive controls still has the visible slight chronic congestion of part animal naked eyes, the mucosa glossiness is not good enough, and secretions is more.The pharyngeal epithelial proliferation is lighter, and is congested light in the lamina propria, and the small part cell infiltration is arranged in the pipe, and the fibroplasia phenomenon is arranged in the few animals lamina propria, and all the other do not see obvious pathological changes.As seen the compound spray group is compared the folk prescription group and is had better antiinflammatory synergism.2.2 cotton balls is brought out the influence of rat granulation tissue hyperplasia
Get 50 of male SD rats, be divided into 5 groups at random, 10 every group.Be normal saline matched group, formed 3 the treatment groups of three kinds of sprays of the present invention, dexamethasone sodium phosphate matched group.Under aseptic condition, in the rat back otch, the sterilized cotton ball of the heavily about 20mg of subcutaneous implantation one is sewed up the incision, and the part is coated with the kanamycin of 12.5 * 105U/L.From burying the same day of cotton balls, every day, each group was sprayed normal saline, three kinds of sprays of the present invention, the positive control solution of equivalent (0.5ml), every day 3 times, logotype 10d in cotton balls external skin place.Take off cervical vertebra after the 10th and put to death, take out cotton balls 60 ℃ of oven dry, weigh, the weight that deducts cotton balls is the weightening finish of granulation (the results are shown in Table 1).
The experimental result of table 1 shows: three kinds of sprays of the present invention can significantly suppress to bury the rat granuloma that cotton balls brings out.The positive control dexamethasone sodium phosphate also has inhibitory action to the rat granuloma of burying cotton balls and bringing out, but suppression ratio is starkly lower than three kinds of sprays of the present invention.Illustrate that three kinds of compound sprays of the present invention have unique therapeutic effect to the rat granuloma of burying cotton balls and bringing out, evident in efficacyly be better than single dexamethasone sodium phosphate group of using.
Table l three kinds of sprays of the present invention to bury cotton balls bring out the granulomatous influence of rat (X ± s, n=10)
2.3 anti-microbial property test
2.3.1 the mensuration of bacteriostasis rate
Taking by weighing 6 parts of compound sprays that contain the chlorhexidine composition after sterilization treatment is mixed with and is respectively 200,400,800,1000,1200 μ g/ml suspensions, join in the culture fluid that contains certain bacterium amount, shaken cultivation 24h in the time of 37 ℃ then, after each test tube shakes up, the mixed liquor 100 μ L that take out after cultivating are added on the enzyme reaction plate respectively, the place measures the OD value in enzyme mark analyzer 570nm wavelength, calculates the bacteriostasis rate of antibacterial, the results are shown in Table 2.
Survival rate %=OD570 (after adding medicinal liquid)/OD570 (not adding medicinal liquid)
Bacteriostasis rate %=1-survival rate %
Table 2 variable concentrations chlorhexidine bacteriostasis rate
The result shows: along with the increase of chlorhexidine concentration, antibacterial ability strengthens.
2.3.2 antibacterial ring test
E.coli (ATCC25922), S.aureus (ATCC25923) are cultivated 24h with broth bouillon at 37 ℃, it is stand-by to make bacteria suspension, the nutrient agar pour plate, solidify, respectively get the 0.5mL bacteria suspension with aseptic straw and inject the agar culture medium 150mL that is chilled to about 45 ℃, make bacteria suspension full and uniform dispersion in the agar culture medium that melts.Then be injected into solidify, uniformly on the low layer agar culture medium, rotation immediately shakes up, and treats after its natural condensation standby.Drop in gently on the culture medium taking out the spray 100 μ L sterilized, cultivate 24h for 37 ℃, observe its antibacterial ring and take pictures.
The result shows: tangible antibacterial ring is arranged around compound spray (the containing chlorhexidine concentration 1000 μ g/ml) drop.
2.3 antitussive effect research
2.3.1 the foundation and the screening of cough animal model
Draw to cough with ammonia and set up the animal cough model and screen qualified mice, cause mouse cough with ultrasound atomizer aerosol ammonia.With multi-path physiology signal acquiring system Rm6240 record cough number of times.Concrete operations are: Kunming mouse is put into the wide mouthed bottle of traverse, and bottleneck is with the rubber stopper jam-pack of making a call to two holes, the hose connection ultrasound atomizer in one of them hole, hose connection physiograph in another hole.The clip that adds the stressed joint nebulizer writes down normal respiratory wave 10s, then opens clip, open nebulizer simultaneously, spraying 4mol/L ammonia 30s clamps two clips then rapidly, close nebulizer, the respiratory wave of record 3min, mouse cough number of times in the record 3min.The cough number of times is to be the mice of successful modeling 15-30 time in the 3min.
2.3.2 animal grouping and administration
Get 40 of 20g-24g success modeling mices, male female dual-purpose.Be divided into 4 groups by cough number of times and sex stratified random, intraperitoneal injection of saline and contain diammonium glycyrrhizinate concentration and be respectively 0.0625%, 0.125%, 0.25% compound spray respectively, behind the 20min, ammonia draws to be coughed, cough number of times in the record 3min.
2.3.3 statistical procedures
Experimental data represents that with X ± s group difference is checked with t, the results are shown in Table 3.
The spray antitussive effect of the different diammonium glycyrrhizinate concentration of table 3
The result: diammonium glycyrrhizinate is respectively organized the mouse cough number of times and is obviously reduced (p≤≤ 0.01) than the normal saline group, more all has notable difference (P≤0.01) between each group group of diammonium glycyrrhizinate.Conclusion: contain certain density diammonium glycyrrhizinate compound spray and have tangible antitussive effect.When diammonium glycyrrhizinate concentration reached 0.25%, the antitussive effect was better.
3 discuss
Experiment shows that three kinds of compound sprays of the present invention have significant antiinflammatory action, can resist the pharyngitis symptom of animal pattern, and compares with positive controls and to have significant difference (p＜0.05).Bacteriostatic test shows that the variable concentrations compound spray is all better to the inhibition effect of E.coli and S.aureus, reaches when chlorhexidine concentration is 1000 μ g/ml and reaches maximum Mlc substantially, and the fungistatic effect during with 1200 μ g/ml is (p＞0.05) quite.Antitussive effect studies show that when diammonium glycyrrhizinate concentration reached 0.25%, the antitussive effect was better.
Claims (7)
1. pharmaceutical composition for the treatment of acute/chronic pharyngitis, it is characterized in that described pharmaceutical composition comprises the effective ingredient of following components by weight percent: glucocorticoid medicine 0.01-1.00%, antiinflammatory antiseptic 0.01-0.50%, Radix Glycyrrhizae acids medicine 0.02-1.00%.
2. pharmaceutical composition according to claim 1 is characterized in that, glucocorticoid medicine is dexamethasone or derivatives thereof, triamcinolone acetonide or derivatives thereof, budesonide or derivatives thereof, hydrocortisone or derivatives thereof in the described pharmaceutical composition; The antiinflammatory antiseptic is the chlorhexidine or derivatives thereof; Radix Glycyrrhizae acids medicine is glycyrrhizic acid, ammonium glycyrrhizinate, diammonium glycyrrhizinate.
3. pharmaceutical composition according to claim 1, it is characterized in that described pharmaceutical composition comprises the effective ingredient of following components by weight percent: glucocorticoid medicine 0.05-0.15%, antiinflammatory antiseptic 0.05-0.10%, Radix Glycyrrhizae acids medicine 0.1-0.3%.
4. according to arbitrary described pharmaceutical composition among the claim 1-3, it is characterized in that described pharmaceutical composition is tablet, granule, oral administration solution, spray, nasal drop.
5. pharmaceutical composition according to claim 3 is characterized in that, described pharmaceutical composition is spray, buccal tablet and nasal drop.
6. pharmaceutical composition according to claim 4, the preparation method that it is characterized in that described spray or nasal drop is as follows: with chlorhexidine acetate 0.5～1g 300ml dissolved in distilled water, add the Tween 80 of 5～50g with the 300ml dissolved in distilled water, behind the stirring and dissolving mixing, add respectively again dissolving 0.5～1.5g glucocorticoid medicine aqueous solution 100ml, dissolving 1～3g diammonium glycyrrhizinate aqueous solution 100ml and be dissolved in the 5g Mentholum of 200ml hot water, ultrasonic mix homogeneously gets final product.
7. pharmaceutical composition according to claim 4, the preparation method that it is characterized in that described buccal tablet is as follows: glucocorticoid medicine 0.4-1.5g, chlorhexidine acetate 0.4-1.5g, diammonium glycyrrhizinate 0.8-2.5g, respectively with 100g Fructus Hordei Germinatus glucide mixing, sieve, add the 450g Icing Sugar again, sieve, obtain mixed-powder; Will be an amount of (buccal tablet weight 0.5%) Mentholum be dissolved in the 150ml dehydrated alcohol, add mix homogeneously in the mixed powder, oven dry, with 100ml 60% syrup or 1%HPMC solution 120ml is binding agent, system soft material and granulations of sieving, granulate tabletting, compound recipe buccal tablet that must the heavily about 0.4-1.5g/ sheet of sheet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101084275A CN101757629B (en) | 2010-02-05 | 2010-02-05 | Medicine composition for treating acute and chronic aryngitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101084275A CN101757629B (en) | 2010-02-05 | 2010-02-05 | Medicine composition for treating acute and chronic aryngitis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101757629A true CN101757629A (en) | 2010-06-30 |
| CN101757629B CN101757629B (en) | 2011-09-14 |
Family
ID=42489112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101084275A Expired - Fee Related CN101757629B (en) | 2010-02-05 | 2010-02-05 | Medicine composition for treating acute and chronic aryngitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101757629B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2538433C1 (en) * | 2013-06-11 | 2015-01-10 | Закрытое акционерное общество "ФИРН М" (ЗАО ФИРН М") | Pharmaceutical composition for preventing and treating infectious-inflammatory diseases of various origins by oromucosal administration |
| CN106421137A (en) * | 2016-11-17 | 2017-02-22 | 郑州郑先医药科技有限公司 | Compound preparation for treating chronic pharyngitis |
| CN107982282A (en) * | 2017-12-14 | 2018-05-04 | 吉林大学 | A kind of gargle for being used to alleviating and treating pharyngitis |
| CN113197904A (en) * | 2021-03-31 | 2021-08-03 | 和田维吾尔药业股份有限公司 | Traditional Chinese medicine active ingredient composition for treating cough and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1180771C (en) * | 2003-04-15 | 2004-12-22 | 上海医药工业研究院 | Oral cavity adhesive plaster composition for curing gingival disease, laryngopharyngitis and halitosis |
| TW200621315A (en) * | 2004-10-28 | 2006-07-01 | Kowa Co | Orally dissolving solid preparation |
| CN1772073B (en) * | 2005-10-24 | 2010-09-08 | 泸州医学院 | Medicine composition for treating throat and oral cavity diseases and its preparation process |
-
2010
- 2010-02-05 CN CN2010101084275A patent/CN101757629B/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2538433C1 (en) * | 2013-06-11 | 2015-01-10 | Закрытое акционерное общество "ФИРН М" (ЗАО ФИРН М") | Pharmaceutical composition for preventing and treating infectious-inflammatory diseases of various origins by oromucosal administration |
| CN106421137A (en) * | 2016-11-17 | 2017-02-22 | 郑州郑先医药科技有限公司 | Compound preparation for treating chronic pharyngitis |
| CN107982282A (en) * | 2017-12-14 | 2018-05-04 | 吉林大学 | A kind of gargle for being used to alleviating and treating pharyngitis |
| CN113197904A (en) * | 2021-03-31 | 2021-08-03 | 和田维吾尔药业股份有限公司 | Traditional Chinese medicine active ingredient composition for treating cough and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101757629B (en) | 2011-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101757629B (en) | Medicine composition for treating acute and chronic aryngitis and preparation method thereof | |
| CN104116734A (en) | Pharmaceutical composition and pharmaceutical preparation for treating oral and throat diseases, and applications and preparation method of the pharmaceutical composition and pharmaceutical preparation | |
| CN104257794B (en) | Chinese medicine composition of a kind of spleen reinforcing removing food stagnancy and preparation method thereof | |
| CN106822357A (en) | The preparation method and product of a kind of Chinese medicine composition and its deep processing with function of moistening and cleaning throat | |
| CN105851592A (en) | Sow mastitis feed additive with slow-release effect and preparation method | |
| CN102240353A (en) | Traditional Chinese drug anesthetic and preparation method thereof | |
| CN107184807A (en) | A kind of anti-acne detumescence facemask powder | |
| CN103623267A (en) | Medication for treating allergic rhinitis | |
| CN101049485A (en) | Mulberry - ginger soft capsule for treating common cold, and preparation method | |
| CN103704514B (en) | Feed being used for the treatment of porcine contagious pleuropneumonia and preparation method thereof | |
| CN102614269B (en) | Method for preparing traditional Tibetan medicine for treating pharyngitis | |
| CN101804072B (en) | Calculus bovis factitius superfine powder and preparation method | |
| CN104587032B (en) | The anti-cold and hot cataclysm of milk cow spring and sandstorm stress mongolian veterinary drug | |
| WO2017185596A1 (en) | Polyhexamethylene guanidine medicament for treating gastrointestinal diseases, method for preparing same and use thereof | |
| CN105853855A (en) | Incense capable of removing eczema and preparation method thereof | |
| CN104887945B (en) | It is a kind of to be used to treat Chinese medicine composition of lamb pneumonia and its preparation method and application | |
| CN104146558A (en) | Medical pillow capable of treating rhinitis | |
| CN1089596C (en) | Cough and asthma curing plaster stuck to acupoint | |
| CN103041011B (en) | Oral drug for treating gosling candidiasis | |
| CN110179884B (en) | Tincture for infectious dermatitis and preparation method and application thereof | |
| CN109833352A (en) | The preparation process of Erhuang antidiarrheal enteric-coated micro-pill | |
| CN106729631A (en) | Treat the externally applied spray of intractable skin ulcer | |
| CN106728167A (en) | A kind of burn and scald external application sterilizing and itch-relieving ointment | |
| CN105343272A (en) | Medicine for treating miliaria and preparation method thereof | |
| CN1259921C (en) | New medicine for treating beriberi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210628 Address after: 100142 courtyard 30, Fucheng Road, Haidian District, Beijing Patentee after: AIR FORCE SPECIALTY MEDICAL CENTER OF PLA Address before: 100036 No. 30 Fu Cheng Road, Haidian District, Beijing (General Hospital of the Air Force PLA pharmacy department) Patentee before: Zhang Fucheng Patentee before: Wu Yan Patentee before: Xu Rong |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110914 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |